Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease

NeuroImage

Volumn 61, Issue 1, 2012, Pages 228-239

  Ohlin, K Elisabet ^a   Sebastianutto, Irene ^a   Adkins, Chris E ^b   Lundblad, Cornelia ^c   Lockman, Paul R ^b   Cenci, M Angela ^a  

^a LUND UNIVERSITY   (Sweden)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Astrocyte; Cerebrovascular; Levodopa; Motor complications; Neurovascular coupling; Parkinsonism

Indexed keywords

2 AMINO 2 METHYLPROPIONIC ACID C 14; DEOXYGLUCOSE C 14; GLUCOSE; IODOPHENAZONE C 14; LEVODOPA; OXIDOPAMINE; SODIUM CHLORIDE; TRACER; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; DYSKINESIA; ENTOPENDUNCULAR NUCLEUS; FEMALE; GLOBUS PALLIDUS; GLUCOSE UTILIZATION; MOTOR CORTEX; NONHUMAN; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS RETICULATA;

ALGORITHMS; ANIMALS; ANTIPARKINSON AGENTS; AUTORADIOGRAPHY; BASAL GANGLIA; BEHAVIOR, ANIMAL; BENSERAZIDE; BLOOD-BRAIN BARRIER; CAPILLARIES; CEREBROVASCULAR CIRCULATION; DYSKINESIAS; FEMALE; GLUCOSE; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; LEVODOPA; NERVE TISSUE PROTEINS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 84859078960     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.02.066     Document Type: Article

References (75)

1. Albin R.L., Young A.B., Penney J.B. The functional anatomy of the basal ganglia. Trends Neurosci. 1989, 12:366-374.
2. Alonso G., Galibert E., Duvoid-Guillou A., Vincent A. Hyperosmotic stimulus induces reversible angiogenesis within the hypothalamic magnocellular nuclei of the adult rat: a potential role for neuronal vascular endothelial growth factor. BMC Neurosci. 2005, 6:20.
3. Attwell D., Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci. 2002, 25:621-625.
4. Bartels A.L., Willemsen A.T.M., Kortekaas R., de Jong B.M., de Vries R., de Klerk O., van Oostrom J.C.H., Portman A., Leenders K.L. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J. Neural Transm. 2008, 115:1001-1009.
5. Bentzer P., Mattiasson G., McIntosh T.K., Wieloch T., Grande P.O. Infusion of prostacyclin following experimental brain injury in the rat reduces cortical lesion volume. J. Neurotrauma 2001, 18:275-285.
6. Bezard E., Crossman A.R., Gross C.E., Brotchie J.M. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J. 2001, 15:1092-1094.
7. Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2001, 2:577-588.
8. Blasberg R.G., Fenstermacher J.D., Patlak C.S. Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. J. Cereb. Blood Flow Metab. 1983, 3:8-32.
9. Borghammer P., Hansen S.B., Eggers C., Chakravarty M., Vang K., Aanerud J., Hilker R., Heiss W.-D., Rodell A., Munk O.L., Keator D., Gjedde A. Glucose metabolism in small subcortical structures in Parkinson's disease. Acta Neurol. Scand. 2011, (E-pub ahead of print).
10. Boyson S.J., McGonigle P., Molinoff P.B. Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J. Neurosci. 1986, 6:3177-3188.
11. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6:389-395.
12. Cenci M.A., Konradi C. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog. Brain Res. 2010, 183:209-233.
13. Cenci M.A., Lindgren H.S. Advances in understanding L-DOPA-induced dyskinesia. Curr. Opin. Neurobiol. 2007, 17:665-671.
14. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
15. Cenci M.A., Odin P., Ohlin K.E. Current options and future prospects for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol. Disord. Drug Targets 2011, 10(6):670-684.
16. Choi J.-K., Chen Y.I., Hamel E., Jenkins B.G. Brain hemodynamic changes mediated by dopamine receptors: role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. Neuroimage 2006, 30:700-712.
17. de la Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., Ruth T.J., Stoessl A.J. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
18. Delfino M., Kalisch R., Czisch M., Larramendy C., Ricatti J., Taravini I.R.E., Trenkwalder C., Murer M.G., Auer D.P., Gershanik O.S. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology 2007, 32:1911-1921.
19. Desai B., Patel A., Schneider J., Carvey P.M., Hendey B. Evidence for angiogenesis in Parkinson's disease, incidental Lewy Body disease, and progressive supranuclear palsy. J. Neural Transm. 2012, 119(1):59-71.
20. Edvinsson L., Hardebo J.E., McCulloch J., Owman C. Vasomotor response of cerebral blood vessels to dopamine and dopaminergic agonists. Adv. Neurol. 1978, 20:85-96.
21. Edvinsson L., McCulloch J., Sharkey J. Vasomotor responses of cerebral arterioles in situ to putative dopamine receptor agonists. Br. J. Pharmacol. 1985, 85:403-410.
22. Ekstrom A. How and when the fMRI BOLD signal relates to underlying neural activity: the danger in dissociation. Brain Res. Rev. 2011, 62:233-244.
23. Engber T.M., Susel Z., Kuo S., Chase T.N. Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization. J. Neurosci. 1990, 10:3889-3895.
24. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa-induced dyskinesias. Mov. Disord. 2007, 22:1379-1389. quiz 1523.
25. Faucheux B.A., Bonnet A.M., Agid Y., Hirsch E.C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999, 353:981-982.
26. Fox P.T., Raichle M.E., Mintun M.A., Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science 1988, 241:462-464.
27. Gerfen C.R., Miyachi S., Paletzki R., Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 2002, 22:5042-5054.
28. Girouard H., Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J. Appl. Physiol. 2006, 100:328-335.
29. Hansson E., Rönnbäck L., Sellström A. Is there a "dopaminergic glial cell"?. Neurochem. Res. 1984, 9:679-689.
30. Hershey T., Black K.J., Stambuk M.K., Carl J.L., McGee-Minnich L.A., Perlmutter J.S. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:12016-12021.
31. Hershey T., Black K.J., Carl J.L., McGee-Minnich L., Snyder A.Z., Perlmutter J.S. Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2003, 74:844-851.
32. Hirano S., Asanuma K., Ma Y., Tang C., Feigin A., Dhawan V., Carbon M., Eidelberg D. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J. Neurosci. 2008, 28:4201-4209.
33. Holschneider D.P., Maarek J.M. Mapping brain function in freely moving subjects. Neurosci. Biobehav. Rev. 2004, 28:449-461.
34. Johansson B., Nilsson B. The pathophysiology of the blood-brain barrier dysfunction induced by severe hypercapnia and by epileptic brain activity. Acta Neuropathol. 1977, 38:153-158.
35. Klein B., Kuschinsky W., Schrock H., Vetterlein F. Interdependency of local capillary density, blood flow, and metabolism in rat brains. Am. J. Physiol. 1986, 251:H1333-H1340.
36. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., Hendrikse N.H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 2005, 57:176-179.
37. Lee J., Zhu W.-M., Stanic D., Finkelstein D.I., Horne M.H., Henderson J., Lawrence A.J., O'Connor L., Tomas D., Drago J., Horne M.K. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 2008, 131:1574-1587.
38. Lindgren H.S., Rylander D., Ohlin K.E., Lundblad M., Cenci M.A. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav. Brain Res. 2007, 177:150-159.
39. Lindgren H.S., Ohlin K.E., Cenci M.A. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 2009, 34:2477-2488.
40. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 2010, 112:1465-1476.
41. Lockman P.R., Mittapalli R.K., Taskar K.S., Rudraraju V., Gril B., Bohn K.A., Adkins C.E., Roberts A., Thorsheim H.R., Gaasch J.A., Huang S., Palmieri D., Steeg P.S., Smith Q.R. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res. 2010, 16:5664-5678.
42. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
43. Mela F., Marti M., Bido S., Cenci M.A., Morari M. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol. Dis. 2011, 45(1):573-582. 2012 Jan, E-pub ahead of print.
44. Mies G. Blood flow dependent duration of cortical depolarizations in the periphery of focal ischemia of rat brain. Neurosci. Lett. 1997, 221:165-168.
45. Mitchell I.J., Cross A.J., Sambrook M.A., Crossman A.R. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neurosci. Lett. 1986, 63:61-65.
46. Mitchell I.J., Boyce S., Sambrook M.A., Crossman A.R. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 1992, 115(Pt. 3):809-824.
47. Miyazaki I., Asanuma M., Diaz-Corrales F.J., Miyoshi K., Ogawa N. Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Res. 2004, 1029:120-123.
48. Mokrý J., Nemecek S. Cerebral angiogenesis shows nestin expression in endothelial cells. Gen. Physiol. Biophys. 1999, 18(Suppl. 1):25-29.
49. Morgante F., Espay A.J., Gunraj C., Lang A.E., Chen R. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 2006, 129:1059-1069.
50. Naydenov A.V., Vassoler F., Luksik A.S., Kaczmarska J., Konradi C. Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia. Acta Neuropathol. 2010, 120:623-631.
51. Nguyen T.V., Brownell A.L., Iris Chen Y.C., Livni E., Coyle J.T., Rosen B.R., Cavagna F., Jenkins B.G. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 2000, 36:57-65.
52. Ohlin K.E., Francardo V., Lindgren H.S., Sillivan S.E., O'Sullivan S.S., Luksik A.S., Vassoler F.M., Lees A.J., Konradi C., Cenci M.A. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain. 2011, 134(Pt 8):2339-2357.
53. Palombo E., Porrino L.J., Bankiewicz K.S., Crane A.M., Sokoloff L., Kopin I.J. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J. Neurosci. 1990, 10:860-869.
54. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 1994, 662:69-74.
55. Pardridge W.M., Oldendorf W.H. Kinetic analysis of blood-brain barrier transport of amino acids. Biochim. Biophys. Acta 1975, 401:128-136.
56. Paulson O.B., Hasselbalch S.G., Rostrup E., Knudsen G.M., Pelligrino D. Cerebral blood flow response to functional activation. J. Cereb. Blood Flow Metab. 2010, 30:2-14.
57. Pavese N., Evans A.H., Tai Y.F., Hotton G., Brooks D.J., Lees A.J., Piccini P. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006, 67:1612-1617.
58. Paxinos G., Watson C. The Rat Brain Steretactic Coordinates 1998, Academic Press Inc., San Diego, CA.
59. Rascol O., Sabatini U., Brefel C., Fabre N., Rai S., Senard J.M., Celsis P., Viallard G., Montastruc J.L., Chollet F. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain 1998, 121(Pt. 3):527-533.
60. Ruscher K., Kuric E., Wieloch T. Levodopa Treatment Improves Functional Recovery after Experimental Stroke. Stroke 2012, 43(2):507-513.
61. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., Descarries L., Cenci M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 2010, 68:619-628.
62. 14C] antipyrine. Am. J. Physiol. 1978, 234:H59-H66.
63. Sandoval K.E., Witt K.A. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol. Dis. 2008, 32:200-219.
64. Seifert G., Steinhauser C. Neuron-astrocyte signaling and epilepsy. Exp. Neurol. 2011, Sep. 7 (e-pub ahead of print).
65. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 1977, 28:897-916.
66. Trugman J.M., Wooten G.F. The effects of L-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra. Brain Res. 1986, 379:264-274.
67. Trugman J.M., Hubbard C.A., Bennett J.P. Dose-related effects of continuous levodopa infusion in rats with unilateral lesions of the substantia nigra. Brain Res. 1996, 725:177-183.
68. Van Vliet E.A., Da Costa Araujo S., Redeker S., Van Schaik R., Aronica E., Gorter J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007, 130:521-534.
69. Westin J.E., Lindgren H.S., Gardi J., Nyengaard J.R., Brundin P., Mohapel P., Cenci M.A. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-l-alanine-induced dyskinesia. J. Neurosci. 2006, 26:9448-9461.
70. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
71. Williams J.L., Shea M., Furlan A.J., Little J.R., Jones S.C. Importance of freezing time when iodoantipyrine is used for measurement of cerebral blood flow. Am. J. Physiol. 1991, 261:H252-H256.
72. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
73. Wooten G.F., Collins R.C. Metabolic effects of unilateral lesion of the substantia nigra. J. Neurosci. 1981, 1:285-291.
74. Zanassi P., Paolillo M., Montecucco A., Avvedimento E.V., Schinelli S. Pharmacological and molecular evidence for dopamine D(1) receptor expression by striatal astrocytes in culture. J. Neurosci. Res. 1999, 58:544-552.
75. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.